8-K: Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update, Highlighting Cash Runway into 2027

Allarity Therapeutics announces its full year 2024 financial results, reporting a strengthened cash position expected to fund operations into 2027 and progress in its stenoparib clinical development program.

Summary

• Allarity Therapeutics reported its full year 2024 financial results and provided a business update.
• The company's cash and cash receivable balance was $20.9 million as of December 31, 2024, and approximately $25 million at the end of Q1 2025, expected to fund operations into 2027.
• A Phase 2 ovarian cancer trial is scheduled to begin enrollment in H1 2025.
• Enrollment in a new Phase 2 SCLC trial, fully funded by the U.S. Veterans Administration, will begin in Q2-Q3 2025.
• The At-the-Market (ATM) program, initiated in March 2024, has been fully utilized and is no longer active.
• Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer patients, with some on treatment for over 17 months.
• The company executed a strategic realignment to focus exclusively on stenoparib, discontinuing other clinical programs.
• A new Phase 2 protocol for stenoparib in platinum-resistant, advanced ovarian cancer patients has been implemented.
• Allarity presented updated Phase 2 clinical data at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting.
• Thomas Jensen was appointed as permanent CEO, and other key leadership appointments were made.
• The company secured a European patent for the DRP companion diagnostic for stenoparib.
• Allarity Medical Laboratory was established as a revenue-generating unit.
• A $5 million share repurchase program was authorized.
• The company finalized a settlement with the SEC and had a class action lawsuit dismissed.
• A 1-for-30 reverse stock split was implemented to maintain Nasdaq listing compliance.
• The company regained compliance with Nasdaq listing requirements.
• R&D expenses were $6.1 million for 2024, compared to $7.1 million for 2023, with a $9.7 million intangible asset impairment charge.
• G&A expenses were $11.4 million for 2024, including a $2.5 million accrual for the SEC settlement, compared to $10.0 million for 2023.
• Net loss was $24.5 million for 2024, compared to $11.9 million for 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss, it has a strong cash position, is advancing its clinical programs, and has resolved regulatory issues. The focus on stenoparib and the DRP technology are also positive developments.

Positives

• The company's cash position is strong, with funding expected into 2027.
• Clinical development of stenoparib is progressing, with new trials planned and existing trials showing promising results.
• The company has streamlined operations and reduced expenses.
• Allarity secured a European patent for the DRP companion diagnostic for stenoparib.
• Allarity Medical Laboratory was established as a revenue-generating unit.
• The company has resolved outstanding regulatory and legal matters.
• A $5 million share repurchase program was authorized, indicating confidence in the company's future.

Negatives

• The company reported a net loss of $24.5 million for 2024, compared to $11.9 million for 2023.
• The company recorded a $9.7 million intangible asset impairment charge in 2024.
• G&A expenses increased to $11.4 million in 2024, including a $2.5 million accrual for the SEC settlement.

Risks

• The company may not be able to secure sufficient capital to support its ongoing and planned clinical development activities.
• Observed clinical benefit may not be replicated in larger or later-stage studies.
• Final trial data may differ materially from interim observations.
• Stenoparib may not receive regulatory approval or achieve commercial success.
• There are potential delays or challenges in patient enrollment, site activation, or data collection.
• The company's DRP companion diagnostic may not be validated or approved for use with stenoparib.
• Broader operational risks related to market conditions, regulatory developments, or unforeseen external events could affect the company's clinical execution or financial trajectory.

Future Outlook

Allarity expects to begin enrollment in a new Phase 2 ovarian cancer trial protocol in H1 2025 and in a new Phase 2 SCLC trial in Q2-Q3 2025, with a cash runway extending into 2027.

Management Comments

• 2024 was a transformational year for Allarity as we made significant progress in advancing stenoparib as a next-generation treatment for advanced ovarian cancer.
• We are now positioned with a cash runway that extends into 2027.
• With this momentum, we are well-positioned to deliver meaningful clinical milestones and create long-term value for patients and shareholders alike.

Industry Context

Allarity's focus on stenoparib, a dual PARP/WNT pathway inhibitor, aligns with the growing interest in targeting the WNT signaling pathway in cancer treatment. The company's DRP companion diagnostic also reflects the industry's move towards personalized medicine.

Comparison to Industry Standards

• Allarity is focused on stenoparib, a dual PARP/WNT pathway inhibitor, which is a novel approach compared to traditional PARP inhibitors like olaparib (Lynparza) from AstraZeneca or rucaparib (Rubraca) from Clovis Oncology, which primarily target PARP1/2.
• The company's focus on platinum-resistant ovarian cancer aligns with the industry's need for effective treatments in this difficult-to-treat population, similar to efforts by companies like Immunogen with their antibody-drug conjugate mirvetuximab soravtansine (Elahere).
• Allarity's use of the DRP companion diagnostic is similar to other personalized medicine approaches in oncology, such as Foundation Medicine's FoundationOne CDx, which helps identify patients who may benefit from specific targeted therapies.

Management Changes

Corporate Governance

Legal Proceedings

• The company finalized a settlement with the SEC, resolving all outstanding regulatory matters related to past disclosures by prior management regarding FDA interactions on the Dovitinib NDA.
• A class action lawsuit was dismissed, closing all related shareholder litigation.

Stakeholder Impact

• Shareholders: The company's strengthened financial position and clinical progress are positive for shareholders, as is the share repurchase program.
• Employees: The strategic realignment and cost-reduction initiatives may have impacted employees.
• Patients: The advancement of stenoparib and the DRP technology could potentially benefit patients with ovarian cancer and other cancers.
• U.S. Veterans Administration: The VA is a key stakeholder through its funding of the SCLC trial.

Next Steps

• Begin enrollment in the new Phase 2 ovarian cancer trial protocol in H1 2025.
• Initiate patient enrollment in the new Phase 2 SCLC trial in Q2-Q3 2025.
• Continue advancing the clinical development of stenoparib.
• Pursue potential legal action against illegal short selling.

Key Dates

Keywords

Allarity Therapeutics, stenoparib, ovarian cancer, SCLC, clinical trials, DRP, financial results, cash runway, NASDAQ: ALLR, biopharmaceutical